• COVID-safe measures such as telehealth consults for trials, and local deliveries of trial medicines are now serving to improve clinical trial processes beyond the pandemic
• Australia’s contribution to global clinical trials continues to grow, telehealth and other digital measures offer potential to increase access via ‘teletrials’
• In 2020 Novartis contributed to 141 Australian studies, with an investment of AUD20m1
Novartis Australia, and its generics and biosimilars division Sandoz, has confirmed that it will be working with the Australian government to provide an initial supply of generic hydroxychloroquine to support the COVID-19 pandemic response.
Novartis in Australia and New Zealand continues to closely monitor and respond to the coronavirus (COVID-19) situation. Our priority is to ensure the health and safety of our people, patients, and healthcare professionals.
The Novartis community would like to express our thoughts and condolences to all of those affected by the bushfires in Australia.
Up to 8,800 hospital admissions and hundreds of deathscould be prevented, according to first Seasonal Vulnerability Report1
Thousands of older Australians are being hospitalised as temperatures plummet across Australia, with a new report revealing a 32 per cent spike in admissions during winter compared to summer for deadly and common heart conditions.1
This site is intended for an audience in Australia